Emerging critical role of molecular testing in diagnostic genitourinary pathology

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 4, 2012, Pages 372-390

  Netto, George J ^a   Cheng, Liang ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BLADDER TUMOR; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; GENETICS; GENOMICS; HUMAN; KIDNEY CARCINOMA; MALE; MOLECULAR PATHOLOGY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; URINARY TRACT CANCER;

ADENOCARCINOMA; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GENOMICS; HUMANS; MALE; PATHOLOGY, MOLECULAR; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84859999852     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0471-RA     Document Type: Article

References (308)

1. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol. 2006;24:5552-5564. (Pubitemid 46631336)
2. Mitra AP, Cote RJ. Molecular screening for bladder cancer: progress and potential. Nat Rev Urol. 2010;7:11-20.
3. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol. 2009;4:251-285.
4. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5:713-725.
5. Oxford G, Theodorescu D. The role of ras superfamily proteins in bladder cancer progression. J Urol. 2003;170:1987-1993. (Pubitemid 37254994)
6. Lopez-Knowles E, Hernandez S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006;66:7401-7404. (Pubitemid 44289191)
7. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5:e13821. doi:10.1371/journal.pone.0013821.
8. Kubota Y, Miyamoto H, Noguchi S, et al. The loss of retinoblastoma gene in association with c-myc and transforming growth factor-beta 1 gene expression in human bladder cancer. J Urol. 1995;154:371-374.
9. O'Donnell MA. Advances in the management of superficial bladder cancer. Semin Oncol. 2007;34:85-97. (Pubitemid 46436121)
10. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon,France: IARC Press; 2004. World Health Organization Classification of Tumours; vol 7.
11. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675. (Pubitemid 32120143)
12. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium, J Urol. 2006;176:2414-2422. (Pubitemid 44755069)
13. [discussion in J Urol. 2006; 176:2422].
14. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183:68-75.
15. Rabbani F, Koppie TM, Charytonowicz E, Drobnjak M, Bochner BH, Cordon-Cardo C. Prognostic significance of p27(Kip1) expression in bladder cancer. BJU Int. 2007;100:259-263. (Pubitemid 47036568)
16. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778-789. (Pubitemid 46622045)
17. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 2002;62:6973-6980. (Pubitemid 35424089)
18. Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer. 2003;89:2172-2177. (Pubitemid 38167995)
19. Ioachim E, Michael M, Salmas M, Michael MM, Stavropoulos NE, Malamou-Mitsi V. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesisrelated proteins. Urol Int. 2006;77:255-263. (Pubitemid 44567817)
20. Ioachim E, Michael MC, Salmas M, et al. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer. 2006;6:140.
21. Lascombe I, Clairotte A, Fauconnet S, et al. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res. 2006;12:2780-2787.
22. Rotterud R, Nesland JM, Berner A, Fossa SD. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int. 2005; 95:1344-1350. (Pubitemid 40799457)
23. Highshaw RA, McConkey DJ, Dinney CP. Integrating basic science and clinical research in bladder cancer: update from the first bladder specialized program of research excellence (SPORE). Curr Opin Urol. 2004;14:295-300. (Pubitemid 39141986)
24. Clairotte A, Lascombe I, Fauconnet S, et al. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol. 2006;125:119-126. (Pubitemid 43089734)
25. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;22:1007-1013. (Pubitemid 41095032)
26. Beekman KW, Bradley D, Hussain M. New molecular targets and novel agents in the treatment of advanced urothelial cancer. Semin Oncol. 2007;34: 154-164. (Pubitemid 46436116)
27. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma J Urol. 2007;177:481-487. (Pubitemid 46054033)
28. [discussion in J Urol. 2007;177:487.]
29. Miyamoto H, Kubota Y, Fujinami K, et al. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers. Oncol Res. 1995;7:327-330.
30. Miyamoto H, Kubota Y, Shuin T, et al. Analyses of p53 gene mutations in primary human bladder cancer. Oncol Res. 1993;5:245-249. (Pubitemid 24019009)
31. Birkhahn M, Mitra AP, Williams AJ, et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol. 2010;57:12-20.
32. Cheng L, Davidson DD, Maclennan GT, et al. The origins of urothelial carcinoma. Expert Rev Anticancer Ther. 2010;10:865-880.
33. Mengual L, Burset M, Ribal MJ, et al. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res. 2010;16:2624-2633.
34. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol. 2007;25:468-475. (Pubitemid 350151896)
35. Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Ther. 2010;10: 407-415.
36. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol. 2007;52:1601-1609. (Pubitemid 350052431)
37. Netto GJ. Molecular diagnostics in urologic malignancies: a work in progress. Arch Pathol Lab Med. 2011;135:610-621.
38. Netto GJ, Epstein JI. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology. 2010;42:384-394.
39. Kawauchi S, Sakai H, Ikemoto K, et al. 9p21 index as estimated by dualcolor fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology. Hum Pathol. 2009;40:1783-1789.
40. Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol. 2003;23:41-48.
41. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003;169: 2101-2105. (Pubitemid 36576726)
42. Sarosdy MF, Kahn PR, Ziffer MD, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol. 2006;176:44-47. (Pubitemid 43833178)
43. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer Eur Urol. 2007;51:1275-1280. (Pubitemid 46436295)
44. [discussion in Eur Urol. 2007;51:1280].
45. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295-301. (Pubitemid 46797189)
46. Fritsche HM, Burger M, Dietmaier W, et al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol. 2010;134:597-603.
47. Karnwal A, Venegas R, Shuch B, Bassett J, Rajfer J, Reznichek R. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer. Can J Urol. 2010;17:5077-5081.
48. Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, Lotan Y. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol. 2010;183:62-67.
49. Ferra S, Denley R, Herr H, Dalbagni G, Jhanwar S, Lin O. Reflex UroVysion testing in suspicious urine cytology cases. Cancer. 2009;117:7-14.
50. Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical bacillus calmette-guerin therapy. Int J Cancer. 2009;124:2899-2904.
51. Maffezzini M, Campodonico F, Capponi G, et al. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Res. 2010;30:4761-4765.
52. Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int. 2009;104:336-339.
53. Renshaw AA. UroVysion, urine cytology, and the College of American Pathologists: where should we go from here? Arch Pathol Lab Med. 2010;134: 1106-1107.
54. van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/ MIB1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58:433-441.
55. Mason RA, Morlock EV, Karagas MR, et al. EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis. 2009;30:1155-1160.
56. Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol. 2009;17:198-205.
57. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. HER2/ neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer. 2004;40: 56-63. (Pubitemid 37542318)
58. Gandour-Edwards R, Lara PN Jr, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 2002;95:1009-1015. (Pubitemid 34925350)
59. Eissa S, Ali HS, Al Tonsi AH, Zaglol A, El Ahmady O. HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochem. 2005;38: 142-148. (Pubitemid 40092456)
60. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001; 158:1955-1959. (Pubitemid 32545179)
61. Leibl S, Zigeuner R, Hutterer G, Chromecki T, Rehak P, Langner C. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS. 2008;116:27-32. (Pubitemid 351191103)
62. Bolenz C, Shariat SF, Karakiewicz PI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 2010;106: 1216-1222.
63. Al-Ahmadie HA, Iyer G, Janakiraman M, et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol. 2011;224:270-279.
64. Ling S, Chang X, Schultz L, et al. An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res. 2011;71: 3812-3821.
65. Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res. 2010;16: 3011-3018.
66. Miyake M, Sugano K, Sugino H, et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci. 2010;101: 250-258.
67. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24:3664-671. (Pubitemid 46630542)
68. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003;21:1912-1921. (Pubitemid 46606378)
69. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol. 2006;49:466-465.
70. [discussion in Eur Urol. 2006;49:475-477].
71. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 2005;62:309-317. (Pubitemid 40704444)
72. Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001;7: 2440-2447. (Pubitemid 32751647)
73. Ravery V, Grignon D, Angulo J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res. 1997;25:9-17. (Pubitemid 27141798)
74. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993;85:53-59. (Pubitemid 23023225)
75. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 1994;152:388-392. (Pubitemid 24221226)
76. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995;13:1384-1390.
77. 21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer. 2004;100:1859-1867. (Pubitemid 38529563)
78. Tzai TS, Tsai YS, Chow NH. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol. 2004;22:112-118.
79. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67- MIB1). Eur Urol. 2004;45:606-612. (Pubitemid 38481688)
80. Shariat SF, Bolenz C, Karakiewicz PI, et al. P53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010;105:489-495.
81. Lopez-Beltran A, Requena MJ, Luque RJ, et al. Cyclin D3 expression in primary Ta/T1 bladder cancer. J Pathol. 2006;209:106-113.
82. Fu TY, Tu MS, Tseng HH, Wang JS. Overexpression of p27kip1 in urinary bladder urothelial carcinoma. Int J Urol. 2007;14:1084-1087.
83. Yin M, Bastacky S, Parwani AV, McHale T, Dhir R. P16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol. 2008; 39:527-535.
84. Kruger S, Mahnken A, Kausch I, Feller AC. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol. 2005;47:463-467. (Pubitemid 40357889)
85. Sgambato A, Migaldi M, Faraglia B, et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res. 1999;59:3245-3250. (Pubitemid 29316029)
86. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112:315-325.
87. Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy J Urol. 2009;182:78-84.
88. [discussion in J Urol. 2009;182:84].
89. Dalbagni G, Presti JC Jr, Reuter VE, et al. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol. 1993;2:4-13. (Pubitemid 23197492)
90. Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol. 2006;59:83-88. (Pubitemid 43076244)
91. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12:7369-7373. (Pubitemid 46095410)
92. Margulis V, Lotan Y, Karakiewicz PI, et al. Multi-institutional validation of the predictive value of ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009;101:114-119.
93. Ramos D, Ruiz A, Morell L, et al. Prognostic value of morphometry in low grade papillary urothelial bladder neoplasms. Anal Quant Cytol Histol. 2004;26: 285-294. (Pubitemid 39458648)
94. Cheng L, Zhang S, Maclennan GT, Williamson SR, Lopez-Beltran A, Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol. 2011;42(4):455-481.
95. Miyamoto H, Brimo F, Schultz L, et al. Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med. 2010;134:1160-1163.
96. Mitra AP, Pagliarulo V, Yang D, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol. 2009;27:3929-3937.
97. Rothman N, Garcia-Closas M, Chatterjee N, et al. A multi-stage genomewide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010;42:978-984.
98. Sanchez-Carbayo M, Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin Oncol. 2007;34:75-84. (Pubitemid 46436122)
99. Serizawa RR, Ralfkiaer U, Steven K, et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer. 2011;129(1):78-87.
100. Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 2010;70:3463-3472.
101. Heidenblad M, Lindgren D, Jonson T, et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics. 2008;1:3.
102. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 2006;25:2685-2696.
103. Nishiyama N, Arai E, Chihara Y, et al. Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. Cancer Sci. 2010;101:231-240.
104. Lin HH, Ke HL, Huang SP, Wu WJ, Chen YK, Chang LL. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol. 2010;28:597-602.
105. Vinci S, Giannarini G, Selli C, et al. Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of nonmuscle- invasive urothelial carcinoma of the bladder: a prospective, two-center validation study. Urol Oncol. 2011;29(2):150-156.
106. Cabello MJ, Grau L, Franco N, et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn. 2011;13:29-40.
107. Vallot C, Stransky N, Bernard-Pierrot I, et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst. 2011;103:47-60.
108. Dudziec E, Miah S, Choudhry H, et al. Hypermethylation of CpG islands and shores around specific MicroRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin Cancer Res. 2011;17(6):1287-1296.
109. Wiklund ED, Bramsen JB, Hulf T, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2011;128:1327-1334.
110. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23:2903-2910. (Pubitemid 46224108)
111. Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res. 2004;10:7457-7465. (Pubitemid 39557507)
112. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002;8:464-470. (Pubitemid 34193966)
113. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene. 2006;25:1984-1988.
114. Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst. 2006;98:996-1004. (Pubitemid 44288164)
115. Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res. 2007;13:2046-2053. (Pubitemid 46649871)
116. Ali-El-Dein B, Sarhan O, Hinev A, Ibrahiem eI, Nabeeh A, Ghoneim MA. Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index. BJU Int. 2003;92:393-399. (Pubitemid 37100517)
117. Loughman NT, Lin BP, Dent OF, Newland RC. DNA ploidy of bladder cancer using bladder biopsy supernate specimens. Anal Quant Cytol Histol. 2003;25:146-158. (Pubitemid 36702641)
118. Baak JP, Bol MG, van Diermen B, et al. DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality. Urology. 2003;61: 1266-1272. (Pubitemid 36694031)
119. Bol MG, Baak JP, Diermen B, Janssen EA, Buhr-Wildhagen SB, Kjellevold KH. Correlation of grade of urothelial cell carcinomas and DNA histogram features assessed by flow cytometry and automated image cytometry. Anal Cell Pathol. 2003;25:147-153. (Pubitemid 36693701)
120. Bellaoui H, Chefchaouni MC, Lazrak N, Khalfaoui LC, Yassine F, Elhamany Z. Flow cytometric DNA analysis and cytology in diagnosis and prognosis of bladder tumors: preliminary results of a comparative study of bladder lavage [in French]. Ann Urol (Paris). 2002;36:45-52. (Pubitemid 34106882)
121. Caraway NP, Khanna A, Payne L, Kamat AM, Katz RL. Combination of cytologic evaluation and quantitative digital cytometry is reliable in detecting recurrent disease in patients with urinary diversions. Cancer. 2007;111:323-329.
122. Falkman K, Tribukait B, Nyman CR, Larsson P, Norming U. S-phase fraction in superficial urothelial carcinoma of the bladder-a prospective, longterm, follow-up study. Scand J Urol Nephrol. 2004;38:278-284. (Pubitemid 39277286)
123. Lin J, Dinney CP, Grossman HB, et al. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet. 2006;70:240-245. (Pubitemid 44219512)
124. Palit V, Phillips RM, Puri R, Shah T, Bibby MC. Expression of HIF-1alpha and glut-1 in human bladder cancer. Oncol Rep. 2005;14:909-913.
125. Chai CY, Chen WT, Hung WC, et al. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol. 2008;61:658-664.
126. Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol. 1999;161:799-804. (Pubitemid 29422369)
127. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57:5281-5285. (Pubitemid 27516364)
128. Turner KJ, Crew JP, Wykoff CC, et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer. 2002;86:1276-1282.
129. Tickoo SK, Milowsky MI, Dhar N, et al. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int. 2011;107:844-849.
130. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15:6008-6017.
131. Schultz L, Albadine R, Hicks J, et al. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer. 2010;116:5517-5526.
132. Comperat E, Camparo P, Haus R, et al. Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows Arch. 2007;450:419-424. (Pubitemid 46466396)
133. Mhawech-Fauceglia P, Fischer G, Beck A, Cheney RT, Herrmann FR. Raf1, aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/ pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol. 2006;32:439-444.
134. Veerla S, Panagopoulos I, Jin Y, Lindgren D, Hoglund M. Promoter analysis of epigenetically controlled genes in bladder cancer. Genes Chromosomes Cancer. 2008;47:368-378. (Pubitemid 351451791)
135. Wszolek MF, Rieger-Christ KM, Kenney PA, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol. 2011;29(6):794-801.e1.
136. Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009;69:8472-8481.
137. Iyer G, Milowsky MI, Bajorin DF. Novel strategies for treating relapsed/ refractory urothelial carcinoma. Expert Rev Anticancer Ther. 2010;10:1917- 1932.
138. Wallerand H, Reiter RR, Ravaud A. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Curr Opin Urol. 2008;18:524-532.
139. Amit D, Tamir S, Birman T, Gofrit ON, Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences. Int J Clin Exp Med. 2011;4:91-102.
140. Gerullis H, Ecke TH, Janusch B, et al. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance. Anticancer Drugs. 2011;22(9):940-943.
141. Yafi FA, North S, Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol. 2011;18:e25-e34.
142. Zhang X, Godbey WT. Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma. Cancer Gene Ther. 2011;18:34-41.
143. Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Curr Opin Mol Ther. 2010;12:607-616.
144. Kramer MW, Krege S, Peters I, Merseburger AS, Kuczyk MA. Targeted therapy of urological tumours. experimental field or established therapeutic approach? [in German] Urologe A. 2010;49:1260-1265.
145. Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest. 2010;90:1406-1414.
146. Black PC, Agarwal PK, Dinney CP. Targeted therapies in bladder cancer-an update. Urol Oncol. 2007;25:433-438. (Pubitemid 47362765)
147. Black PC, Dinney CP. Bladder cancer angiogenesis and metastasis- translation from murine model to clinical trial. Cancer Metastasis Rev. 2007;26:
148. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22. (Pubitemid 37328883)
149. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003; 46(suppl):S85-S104. (Pubitemid 36808975)
150. Wallerand H, Robert G, Bernhard JC, Ravaud A, Ferriere JM. Targeted therapy for locally advanced and/or metastatic bladder cancer. Prog Urol. 2008; 18:407-417.
151. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial. J Clin Oncol. 2007;25:2218-2224. (Pubitemid 46954646)
152. Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol. 2008;130:274-281.
153. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res. 2000;6:4874-4884. (Pubitemid 32110432)
154. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999;5:257-265. (Pubitemid 29085177)
155. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ; Cancer and Leukaemia Group B. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the cancer and leukaemia group B 90102. BJU Int. 2008;101:20-25. (Pubitemid 350233568)
156. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ; Cancer and Leukemia Group B. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of cancer and leukemia group B (CALGB) 90102. Ann Oncol. 2009;20:1074-1079.
157. Wulfing C, Machiels JP, Richel DJ, et al. A single-arm, multicenter, openlabel phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115: 2881-2890.
158. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29:1525-1530.
159. Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr Oncol Rep. 2009;11:244-249.
160. Bradley DA, Dunn R, Nanus D, et al. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer. 2007;5:460-463. (Pubitemid 351219702)
161. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Noninvasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int. 2010;60:1-8.
162. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163:73-78.
163. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol. 2002;167:1573-1583. (Pubitemid 34240678)
164. Malekzadeh K, Sobti RC, Nikbakht M, et al. Methylation patterns of Rb1 and casp-8 promoters and their impact on their expression in bladder cancer. Cancer Invest. 2009;27:70-80.
165. van der Kwast TH, Bapat B. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling. Curr Opin Urol. 2009;19: 516-521.
166. Wilhelm-Benartzi CS, Koestler DC, Houseman EA, et al. DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer. Carcinogenesis. 2010;31:1972-1976.
167. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
168. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostatecancer mortality in a randomized european study. N Engl J Med. 2009;360:1320-1328.
169. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715-717. (Pubitemid 43821789)
170. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005-7012.
171. Partin AW, Kattan MW, Subong EN, et al. Combination of prostatespecific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA. 1997;277:1445-1451. (Pubitemid 27208886)
172. Amin M, Boccon-Gibod L, Egevad L, et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl. 2005;(216):20-33.
173. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet. 2003;361:955-964. (Pubitemid 36332115)
174. De Marzo AM, DeWeese TL, Platz EA, et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem. 2004;91:459-477.
175. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366-381. (Pubitemid 36886244)
176. Srigley JR, Amin M, Boccon-Gibod L, et al. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl. 2005;(216):8-19.
177. Bethel CR, Faith D, Li X, et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res. 2006; 66:10683-10690. (Pubitemid 44876963)
178. Prowatke I, Devens F, Benner A, et al. Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer. 2007;96:82-88. (Pubitemid 46094643)
179. Khan MA, Partin AW. Tissue microarrays in prostate cancer research. Rev Urol. 2004;6:44-46.
180. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648. (Pubitemid 41528150)
181. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396-3400.
182. Toubaji A, Albadine R, Meeker AK, et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol. 2011;24(11):1511-1520.
183. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009;69:1400-1406.
184. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596-4599. (Pubitemid 47037039)
185. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol. 2009;22(3):359-365.
186. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008;21:1451-1460.
187. FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a populationbased study of prostate cancer. BMC Cancer. 2008;8:230.
188. Mao X, Shaw G, James SY, et al. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian J Androl. 2008;10:467-473. (Pubitemid 351596036)
189. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882-888. (Pubitemid 47165141)
190. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008;14:3395-3400.
191. Falzarano SM, Navas M, Simmerman K, et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol. 2010;23: 1499-1506.
192. Netto GJ. TMPRSS2-ERG fusion as a marker of prostatic lineage in smallcell carcinoma. Histopathology. 2010;57:633.
193. [author reply in Histopathology. 2010;57:633-634].
194. Albadine R, Latour M, Toubaji A, et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol. 2009;22:1415-1422.
195. Rostad K, Hellwinkel OJ, Haukaas SA, et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS. 2009;117:575-582.
196. Rice KR, Chen Y, Ali A, et al. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res. 2010;16:1572-1576.
197. Nguyen PN, Violette P, Chan S, et al. A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Eur Urol. 2011;59:407-414.
198. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12:590-598.
199. Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011;35:1014-1020.
200. Epstein JI, Amin M, Boccon-Gibod L, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005;(216):34-63.
201. Hammond ME, Fitzgibbons PL, Compton CC, et al. Cancer Committee and Conference Participants. College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what: summary document and recommendations for implementation. Arch Pathol Lab Med. 2000;124:958-965. (Pubitemid 30602037)
202. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124:995-1000. (Pubitemid 30602040)
203. Armstrong AJ, Netto GJ, Rudek MA, et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010;16:3057-3066.
204. Kremer CL, Klein RR, Mendelson J, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 2006;66:1203-1212. (Pubitemid 44175342)
205. Sanchez D, Rosell D, Honorato B, Lopez J, Arocena J, Sanz G. Androgen receptor mutations are associated with gleason score in localized prostate cancer. BJU Int. 2006;98:1320-1325. (Pubitemid 44721250)
206. Wikstrom P, Bergh A, Damber JE. Transforming growth factor-beta1 and prostate cancer. Scand J Urol Nephrol. 2000;34:85-94. (Pubitemid 32046846)
207. Wikstrom P, Damber J, Bergh A. Role of transforming growth factor-beta1 in prostate cancer. Microsc Res Tech. 2001;52:411-419. (Pubitemid 32167829)
208. Diaz JI, Mora LB, Austin PF, et al. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology. 1999;53:931-938. (Pubitemid 29196308)
209. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB1 (ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol. 1998;110:443-449. (Pubitemid 28443436)
210. Bubendorf L, Tapia C, Gasser TC, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol. 1998;29:949-954. (Pubitemid 28422042)
211. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996;156:1064-1068. (Pubitemid 26269830)
212. Cheng L, Pisansky TM, Sebo TJ, et al. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res. 1999;5:2820-2823. (Pubitemid 29493957)
213. Stapleton AM, Zbell P, Kattan MW, et al. Assessment of the biologic markers p53, ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998;82:168-175. (Pubitemid 28070494)
214. Vis AN, van Rhijn BW, Noordzij MA, Schroder FH, van der Kwast TH. Value of tissue markers p27(kip1), MIB1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol. 2002; 197:148-154. (Pubitemid 34567601)
215. Bostwick DG, Wheeler TM, Blute M, et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 1996;48:47-57. (Pubitemid 26255958)
216. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer. 1997;79: 772-779. (Pubitemid 27076343)
217. Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate. 2000;42:26-33. (Pubitemid 30004872)
218. Strohmeyer D, Strauss F, Rossing C, et al. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res. 2004;24:1797-1804. (Pubitemid 38954712)
219. Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology. 1998;51:79-85. (Pubitemid 28092510)
220. Gettman MT, Pacelli A, Slezak J, et al. Role of microvessel density in predicting recurrence in pathologic stage T3 prostatic adenocarcinoma. Urology. 1999;54:479-485. (Pubitemid 29407025)
221. Krupski T, Petroni GR, Frierson HF Jr, Theodorescu JU. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology. 2000;55:743-749.
222. Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999;161:1238-1243. (Pubitemid 29426125)
223. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol. 1999;162: 2040-2045.
224. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 1996;156:1511-1516. (Pubitemid 26307649)
225. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res. 1995;1:1295-1300.
226. Moul JW, Bettencourt MC, Sesterhenn IA, et al. Protein expression of p53, bcl-2, and KI-67 (MIB1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer Surgery. 1996;120:159-166.
227. [discussion in Surgery. 1996;120:166-167].
228. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression. Clin Cancer Res. 1999;5:2082-2088. (Pubitemid 29399262)
229. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. 1997;158:131-137. (Pubitemid 27251609)
230. Kuczyk MA, Serth J, Bokemeyer C, et al. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer. 1998;34:679-686.
231. Cheng L, Lloyd RV, Weaver AL, et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res. 2000;6:1896-1899. (Pubitemid 30305087)
232. Wu Y, Chhipa RR, Cheng J, Zhang H, Mohler JL, Ip C. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: Implication for prostate cancer cell survival. Anticancer Res. 2010;30:3895-3901.
233. Bismar TA, Yoshimoto M, Vollmer RT, et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int. 2011;107(3):477-485.
234. Bubendorf L. Words of wisdom, re: aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Eur Urol. 2009; 56:882-883.
235. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22:1083-1093.
236. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41:524-526.
237. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res. 2009;15:4799-4805.
238. Squire JA. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet. 2009;41:509-510.
239. Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer. 2001;95:135-139. (Pubitemid 32477226)
240. Aslan G, Irer B, Tuna B, Yorukoglu K, Saatcioglu F, Celebi I. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features. Pathol Res Pract. 2006;202:93-98. (Pubitemid 43125709)
241. Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21: 1156-1167.
242. Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol. 2008;15:319-331.
243. Veltri RW, Partin AW, Epstein JE, et al. Quantitative nuclear morphometry, markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl. 1994;19:249-258. (Pubitemid 24306476)
244. Ross JS, Sheehan CE, Hayner-Buchan AM, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer. 1997;79:2162-2170. (Pubitemid 27227381)
245. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004; 101:811-816. (Pubitemid 38121040)
246. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39:41-51. (Pubitemid 46026500)
247. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007;67: 8504-8510. (Pubitemid 47437424)
248. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11-22.
249. Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res. 2005;11:4097-4106. (Pubitemid 40791574)
250. Bastian PJ, Nakayama M, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer [in German]. Urologe A. 2004;43:573-579. (Pubitemid 38756570)
251. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res. 2005;11:4037-4043. (Pubitemid 40791567)
252. Bastian PJ, Yegnasubramanian S, Palapattu GS, et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol. 2004;46:698-708. (Pubitemid 39488398)
253. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975-5979. (Pubitemid 30004960)
254. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695-698. (Pubitemid 34462754)
255. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089-1095. (Pubitemid 43794421)
256. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587-1592.
257. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in european men scheduled for repeat biopsy. Eur Urol. 2008;54: 1081-1088.
258. Sokoll LJ, Ellis W, Lange P, et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta. 2008;389:1-6.
259. Aubin SM, Reid J, Sarno MJ, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010;184:1947-1952.
260. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol. 2008; 179:1804-1809.
261. [discussion in J Urol. 2008;179:1809-1810].
262. van Poppel H, Haese A, Graefen M, et al. The relationship between Prostate Cancer gene 3 (PCA3) and prostate cancer significance [published online ahead of print August 26, 2011]. BJU Int. doi:10.1111/j.1464-410X.2011.10377.x.
263. Aubin SM, Reid J, Sarno MJ, et al. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Urology. 2011;78:380-385.
264. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Re. s2008;68: 645-649. (Pubitemid 351206738)
265. Kantoff P. Recent progress in management of advanced prostate cancer. Oncology (Williston Park). 2005;19:631-636. (Pubitemid 350042593)
266. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate. 2001;47:102-110. (Pubitemid 32336579)
267. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 2005;65:2825-2831. (Pubitemid 40490085)
268. Jimeno A, Carducci M. Atrasentan: a rationally designed targeted therapy for cancer. Drugs Today (Barc). 2006;42:299-312. (Pubitemid 43980715)
269. Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther. 2005;5:419-427. (Pubitemid 40894976)
270. Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res. 2006;66:9171-9177. (Pubitemid 44521137)
271. Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate. 2006;66:1359-1370. (Pubitemid 44350361)
272. Ikegami S, Yamakami K, Ono T, et al. Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody. Hum Gene Ther. 2006;17:997-1005. (Pubitemid 46076741)
273. Jayaprakash S, Wang X, Heston WD, Kozikowski AP. Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. ChemMedChem. 2006;1:299-302. (Pubitemid 43700288)
274. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281-291. (Pubitemid 34184451)
275. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005; 23:2763-2771. (Pubitemid 46179466)
276. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-624. (Pubitemid 36514472)
277. Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am. 2008;35:613-625;vii.
278. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005;173:1496-1501. (Pubitemid 40524757)
279. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10:5464-5471. (Pubitemid 39100484)
280. Kluger HM, Siddiqui SF, Angeletti C, et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest. 2008;88:962-972.
281. Hager M, Haufe H, Kemmerling R, et al. Increased activated akt expression in renal cell carcinomas and prognosis. J Cell Mol Med. 2009;13(8B):2181-2188.
282. Eichelberg C, Junker K, Ljungberg B, Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009;55(4):851-863.
283. Djordjevic G, Mozetic V, Mozetic DV, et al. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract. 2007;203:99-106. (Pubitemid 46173164)
284. Bensalah K, Pantuck AJ, Crepel M, et al. Prognostic variables to predict cancer-related death in incidental renal tumours. BJU Int. 2008;102:1376-1380.
285. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007;109:2257-2267. (Pubitemid 46801555)
286. Pantuck AJ, Thomas G, Belldegrun AS, Figlin RA. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol. 2006;33:607-613. (Pubitemid 44540210)
287. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802-811. (Pubitemid 36182618)
288. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714-3721. (Pubitemid 40685588)
289. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58:75-83.
290. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int. 2004;93:297-302. (Pubitemid 38253573)
291. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res. 2005;11:1129-1135. (Pubitemid 40175762)
292. Migita T, Oda Y, Naito S, Tsuneyoshi M. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer. 2002;94:973-979. (Pubitemid 34150851)
293. Hedberg Y, Davoodi E, Ljungberg B, Roos G, Landberg G. Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int J Cancer. 2002;102:601-607. (Pubitemid 35334467)
294. Hedberg Y, Ljungberg B, Roos G, Landberg G. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer. 2003;88:1417-1423. (Pubitemid 36606426)
295. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13:671s-679s.
296. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991-5004. (Pubitemid 46646218)
297. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353: 2477-2490. (Pubitemid 41770167)
298. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von hippel-lindau protein. Proc Natl Acad Sci U S A. 1996;93:10595-10599. (Pubitemid 26333032)
299. Kroog GS, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am. 2008;35:687-701;ix.
300. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008;113: 1552-1558.
301. Bhatia S, Thompson JA. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Adv Ther. 2009;26(1):55-67.
302. Patard JJ, Pouessel D, Bensalah K, Culine S. Targeted therapy in renal cell carcinoma. World J Urol. 2008;26:135-140.
303. Patard JJ, Pouessel D, Culine S. New therapies in renal cell carcinoma. Curr Opin Support Palliat Care. 2007;1:174-179.
304. Patard JJ, Thuret R, Raffi A, Laguerre B, Bensalah K, Culine S. Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol. 2009;55(1):237-239.
305. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010;221:125-138.
306. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277-285.
307. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434. (Pubitemid 36910021)
308. Steffens MG, Boerman OC, de Mulder PH, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res. 1999;5:3268s-3274s. (Pubitemid 29493926)